{"disease":{"id":"carcinoma-advanced-alk-or-ros1-non-small-cell-lung-neoplasm-advanced-alk-or-ros1-solid-tumors","name":"carcinoma advanced alk or ros1 non small cell lung neoplasm advanced alk or ros1 solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03420742","title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Takeda","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}